ClinicalTrials.gg
RecruitingNCT06477536Updated Feb 14, 2025

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

A Phase 2/3 interventional study of HB0034 in Generalized Pustular Psoriasis, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
151st of 182
33 · median 171
Started
2024
with 24 others
Phase 2/3
2 of 206
2 open now
Primary completion
2025-12
later than 13 of 65 live
Registered
135th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 151st largest by planned enrollment of the 182 interventional ones that give a count, is one of 25 that started in 2024, is one of 2 in phase 2/3, reaches primary completion later than 13 of the 65 other live ones, and was the 135th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).

Read the detailed description

This study will also evaluate the pharmacokinetic (PK) profile of HB0034 and explore the immunogenicity of HB0034 in subjects with GPP

03

Conditions studied

  • Generalized Pustular Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients participated in the preceding placebo-controlled Phase 2 study (HB0034-04)and completed at least the Week 12 visit of the HB0034-04 study
  • Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment
  • Men and women of reproductive age who have no parenting plans and are willing to use reliable during the study period and for 6 months after the last dose of the study drug;
  • Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules

Exclusion criteria

Exclusion Criteria:

  • Patients who are experiencing GPP flare
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    HB0034

    single-arm and all the patients would receive HB0034 300mg i.v. every other four weeks

    Drug: HB0034

Interventions

  • DrugHB0034

    300mg, i.v. Q4W

    Also known as: Anti-IL-36R antibody,Recombinant Humanized anti-IL-36R Monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Safety endpoints include the proportion of subjects with TEAEs

    The safety assessment includes monitoring for AEs, SAEs (including SAEs related to protocol procedures from signing of ICF until before the first dose of the study drug) from the first dose of the study drug to end of study (EOS) , as well as changes from baseline in laboratory tests, vital signs, physical examination, and 12-lead electrocardiogram (ECG).

    Time frame: 0-24 weeks

Secondary outcomes

  1. The recurrence of GPP flare during the study

    The Proportion of patients who have at least once GPP flare during the study

    Time frame: 0-24 weeks

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2025, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2024
First posted
Jun 27, 2024
StartActual
Sep 2, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jun 30, 2026
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06477536
Lead sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 27, 2024
Start date
Sep 2, 2024
Primary completion
Dec 30, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Feb 14, 2025

Study contacts

Guodong Zhou
Contact
guodong.zhou@huaota.com
+86 13636638684
Qiaoxia Qian, Master
Contact
qiaoxia.qian@huaota.com
+86 18555690860
Jianzhong Zhang, PhD
principal investigator · Peking University People's Hospital (PKUPH)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HB0034

Start the discussion